[1] Giacco F, Du X, D'Agati VD, et al. Knockdown of glyoxalase 1 mimics diabetic nephropathy in nondiabetic mice[J]. Diabetes, 2014, 63(1): 291-299. [2] Gordin D, Forsblom C, Panduru NM, et al. Osteopontin is a strong predictor of incipient diabetic nephropathy, cardiovascular disease, and all-cause mortality in patients with type 1 diabetes[J]. Diabetes care, 2014, 37(9): 2593-2600. [3] Haneda M, Utsunomiya K, Koya D, et al. A new classification of diabetic nephropathy 2014: a report from Joint Committee on Diabetic Nephropathy[J].J Diabetes Investig, 2015, 6(2): 242-246. [4] Shah A D, Langenberg C, Rapsomaniki E, et al. Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1.9 million people[J]. Lancet Diabetes Endocrinol,2015, 3(2): 105-113. [5] National Kidney Foundation.K/DOQI clinical practice guidelines for chronic kidney disease:evaluation, classification, and stratification[J]. Am J Kidney Dis, 2002,39(2 Suppl 1):S1-S266. [6] 陈景斌, 雷龙涛, 楚英娜, 等. 2 型糖尿病心血管并发症与血浆中 miR-21 及胱抑素 C 表达的相关性研究[J]. 中国糖尿病杂志, 2015, 23(5): 441-444. [7] Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes[J].N Engl J Med,2016,375(4): 323-334. [8] Carlsson AC, stgren CJ, Nystrom FH, et al. Association of soluble tumor necrosis factor receptors 1 and 2 with nephropathy, cardiovascular events, and total mortality in type 2 diabetes[J].cardiovasc Diabetol,2016,15: 40. [9] 黄子芮.内质网应激在糖尿病心血管并发症发生中作用的研究进展[J]. 山东医药, 2016, 56(30): 102-104. [10] de Ferranti SD, De Boer IH, Fonseca V, et al. Type 1 diabetes mellitus and cardiovascular disease: a scientific statement from the American Heart Association and American Diabetes Association[J]. Circulation, 2014, 130(13): 1110-1130. [11] 卞宁. 糖尿病周围神经病变与糖尿病患者潜在心血管疾病风险的关系[J]. 中华临床医师杂志 (电子版), 2015, 9(9): 1698-1700.